• GeNO LLC, of Cocoa, Fla., was issued U.S. Patent Nos. 8,211,368; 8,221,800; 8,226,916; and 8,246,725, which are all in regard to the company's inhaled nitric oxide chemistry and delivery technology. Read More
• Merck KGaA, of Darmstadt, Germany, said its EMD Millipore division entered definitive agreements to acquire Biochrom AG, a Berlin-based firm that specializes in the production and marketing of cell culture media and buffer solutions. Read More
• ActoGeniX NV, of Ghent, Belgium, said Phase I pharmacokinetic data for AG013, an oral rinsing solution in development for the prevention of oral mucositis, showed that the liver AG013 bacteria adhered to the buccal mucosa and actively secreted protein locally, resulting in homogenous exposure to the entire mucosal surface up to 24 hours after administration. Read More
• Dynavax Technologies Corp., of Berkeley, Calif., said the European Medicines Agency (EMA) accepted the marketing authorization application (MAA) filing for Heplisav, pursuing an indication for immunization against infection caused by all known subtypes of hepatitis B virus in adults, ages 18 to 70, and in patients with chronic kidney disease. Read More
A string of first-ever events for Russia, including its official admittance to the World Trade Organization, plus committed government support to build a biopharma industry means the nation once known as the Kremlin may be in need of a more modern nickname as it transforms from an emerging market to one that could compete alongside the U.S., Japan and Europe. Read More
LONDON – A hitch at Algeta ASA's new facility for manufacturing commercial supplies of Alpharadin has pushed back the filing date for the alpha radiation treatment for bone metastases from midyear to the end of 2012. Read More
Sanofi SA is withdrawing the leukemia drug Campath (alemtuzumab), a major bone of contention during the fractious negotiations preceding its 2011 acquisition of Genzyme Corp., in favor of rebranding the CD52-targeting antibody as Lemtrada in the planned indication of multiple sclerosis (MS). Read More
